Iksuda Therapeutics Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.glythera.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)IKS014 in Advanced Solid Tumors That Express HER2
Phase 1
Recruiting
- Conditions
- Breast CancerGastric CancerGastroesophageal-junction Cancer
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Iksuda Therapeutics Ltd.
- Target Recruit Count
- 165
- Registration Number
- NCT05872295
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- Iksuda Therapeutics Limited
- Target Recruit Count
- 80
- Registration Number
- 2024-512415-45-00
- Locations
- 🇺🇸
University of Maryland Baltimore, Baltimore, Maryland, United States
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
News
No news found